This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Next Generation CAR & T Cell Therapies

REGISTER BY FEBRUARY 10 FOR EARLY EVENT PLATFORM ACCESS

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
February 27 - March 2, 2023 | Part of BPI West
San Diego Convention CenterSan Diego, CA

Paul Lammers
CEO at Triumvira Immunologics

Profile

Dr. Lammers, MD, MSc, joined Triumvira Immunologics as President and CEO in January 2018. Before Triumvira, Dr. Lammers served as President/CEO at Mirna Therapeutics, for which company he raised $160 million through venture capital and Federal and State government funding, as well as a public listing on NASDAQ. Previously, he served as Chief Medical Officer and Head of US Product Development for EMD Serono. During his early industry tenure, Dr. Lammers also held various executive/senior management positions in clinical development, medical and regulatory affairs, at different pharmaceutical companies, as well as at small public and privately held biotech companies.

Agenda Sessions

  • TAC-T Cells: Fulfilling the Promise of T Cell Therapy

    2:30pm